Share on StockTwits

Shares of Sequenom (NASDAQ:SQNM) have been given a consensus rating of “Buy” by the eight ratings firms that are currently covering the stock, American Banking News.com reports. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $6.00.

Sequenom (NASDAQ:SQNM) traded up 3.50% on Thursday, hitting $4.109. The stock had a trading volume of 1,606,901 shares. Sequenom has a 52-week low of $1.65 and a 52-week high of $4.90. The stock has a 50-day moving average of $3.22 and a 200-day moving average of $2.64. The company’s market cap is $478.3 million. Sequenom also was the target of a large drop in short interest during the month of June. As of June 13th, there was short interest totalling 22,496,004 shares, a drop of 5.2% from the May 30th total of 23,741,438 shares. Based on an average daily volume of 1,307,209 shares, the short-interest ratio is currently 17.2 days. Approximately 19.5% of the shares of the company are short sold.

Sequenom (NASDAQ:SQNM) last announced its earnings results on Thursday, May 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. The company had revenue of $46.30 million for the quarter, compared to the consensus estimate of $46.06 million. During the same quarter in the prior year, the company posted ($0.26) earnings per share. The company’s quarterly revenue was up 20.3% on a year-over-year basis. Analysts expect that Sequenom will post $-0.35 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Jefferies Group initiated coverage on shares of Sequenom in a research note on Thursday. They set a “buy” rating and a $5.00 price target on the stock. Separately, analysts at William Blair upgraded shares of Sequenom from a “market perform” rating to an “outperform” rating in a research note on Monday, June 23rd. Finally, analysts at Wedbush raised their price target on shares of Sequenom to $5.00 in a research note on Tuesday, June 17th.

Sequenom, Inc (NASDAQ:SQNM) is a molecular diagnostic testing and genetics analysis company committed to providing molecular diagnostic testing services, and research use only products, services, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural, livestock, and other areas of research.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.